Phase 2 placebo-controlled, single-blind trial to evaluate the impact of oral ibandronate on bone mineral density in osteopenic breast cancer patients receiving adjuvant aromatase inhibitors: 5-year results of the single-centre BONADIUV trial

We present the final results of the BONADIUV trial, a single-blind, randomised, placebo-controlled phase 2 study to evaluate the impact of ibandronate treatment on bone mineral density (BMD) in osteopenic women taking aromatase inhibitors (AI).

Source: European Journal of Cancer - January 14, 2019 Category: Cancer & Oncology Authors: Lorenzo Livi, Vieri Scotti, Isacco Desideri, Calogero Saieva, Sara Cecchini, Giulio Francolini, Carlotta Becherini, Camilla Delli Paoli, Luca Visani, Viola Salvestrini, Maria Laura De Feo, Jacopo Nori, Marco Bernini, Luis Sanchez, Lorenzo Orzalesi, Simone Tags: Clinical Trial Source Type: research